MX9603510A - (-)-liarozol enantiomericamente puro. - Google Patents

(-)-liarozol enantiomericamente puro.

Info

Publication number
MX9603510A
MX9603510A MX9603510A MX9603510A MX9603510A MX 9603510 A MX9603510 A MX 9603510A MX 9603510 A MX9603510 A MX 9603510A MX 9603510 A MX9603510 A MX 9603510A MX 9603510 A MX9603510 A MX 9603510A
Authority
MX
Mexico
Prior art keywords
compounds
liarozole
enantiomerically pure
novel
formula
Prior art date
Application number
MX9603510A
Other languages
English (en)
Inventor
Marc Gaston Venet
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX9603510A publication Critical patent/MX9603510A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Abstract

Esta invencion se refiere al isomero levogiro enantioméricamente puro novedoso de la formula I (Ver Formula) y las formas de sal ácida de adicion farmacéuticamente aceptable del mismo; estos compuestos son particularmente utiles para tratar trastornos que se caracterizan por una proliferacion incrementada y/o diferenciacion anormal de células epiteliales normales, preneoplásticas o neoplásticas; los compuestos de la formula (I) son particularmente utiles en el campo de la oncología; también se describen composiciones que contienen dichos compuestos novedosos, métodos para preparar dichos compuestos novedosos así como métodos para usar los compuestos mencionados para tratar los trastornos mencionados.
MX9603510A 1994-02-18 1995-02-10 (-)-liarozol enantiomericamente puro. MX9603510A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94200418 1994-02-18
PCT/EP1995/000491 WO1995022541A1 (en) 1994-02-18 1995-02-10 Enantiomerically pure(-)-liarozole

Publications (1)

Publication Number Publication Date
MX9603510A true MX9603510A (es) 1997-03-29

Family

ID=8216651

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9603510A MX9603510A (es) 1994-02-18 1995-02-10 (-)-liarozol enantiomericamente puro.

Country Status (11)

Country Link
EP (1) EP0745078A1 (es)
JP (1) JPH09508915A (es)
CN (1) CN1141041A (es)
AU (1) AU688852B2 (es)
IL (1) IL112689A0 (es)
MX (1) MX9603510A (es)
NZ (1) NZ279228A (es)
SG (1) SG47122A1 (es)
TW (1) TW418203B (es)
WO (1) WO1995022541A1 (es)
ZA (1) ZA951342B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1992228A1 (en) * 2007-05-14 2008-11-19 Bayer CropScience AG Insecticidal substituted thiourea derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders

Also Published As

Publication number Publication date
AU688852B2 (en) 1998-03-19
EP0745078A1 (en) 1996-12-04
SG47122A1 (en) 1998-03-20
TW418203B (en) 2001-01-11
JPH09508915A (ja) 1997-09-09
CN1141041A (zh) 1997-01-22
NZ279228A (en) 1997-11-24
AU1578895A (en) 1995-09-04
WO1995022541A1 (en) 1995-08-24
IL112689A0 (en) 1995-05-26
ZA951342B (en) 1996-08-19

Similar Documents

Publication Publication Date Title
GR3036816T3 (en) Novel (r)-5-carbamoyl-8-fluoro-3-n,n-disubstituted-amino-3,4-dihydro-2h-1-benzopyranes
YU95102A (sh) Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija
EA200200509A1 (ru) Новые производные бензоимидазола, используемые в качестве антипролиферативного средства
DK0726892T3 (da) (E)-20(22)-dehydrovitamin D-forbindelser
HUT70499A (en) Fluoroalkoxybenzaldehyde derivatives and process for producing them
MXPA05006420A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal.
ZA975439B (en) New pyridyl alkane acid amides.
UA27749C2 (uk) Заміщені циклопропіламіно-1,3,5-триазини, їх оптичні ізомери, рацемічні суміші чи їх солі приєднання нетоксичних фармацевтично прийнятних кислот, що мають фармакологічну активність, спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
NZ512526A (en) 4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin.
BG100661A (en) Aryl acetic acid derivatives
PL336640A1 (en) Substituted 3,3-diamino-2- propenonitriles, their production and application
ES8602792A1 (es) Procedimiento para preparar derivados de purina
MX9603316A (es) (+)-liarozol enantiomericamente puro.
IL166103A0 (en) Pyrrolidine derivatives and their use
MX9603510A (es) (-)-liarozol enantiomericamente puro.
MX9704704A (es) Amidas de acido 4-amino-2-ureido-pirimidin-5-carboxilico, procedimientos para su obtencion, medicamentos que contienen estos compuestos, y su utilizacion.
TNSN86165A1 (fr) Nouveaux ortho-anisamides, leur procede d'obtention et leurs applications therapeutiques
ZA944317B (en) New phosphonosuccinic acid derivatives processes for the preparation thereof and pharmaceutical compositions containing them
DE59406501D1 (de) Substituierte iminoacetonitrile mit myokardprotektiver wirkung